Abiopharma

INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimers Patients

Greenway Announces Second Quarter Financial Statements

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint inAlzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

Altimmune Announces CEO Transition and Succession Plan

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets

Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets